



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", B'WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAM : DOCTORS AID, MUMBAI.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

<http://www.uniquepharma.com>

StockExchange-NSE letters/MM:SA:338

October 19, 2011

National Stock Exchange of India Ltd.
Exchange Plaza, 5th floor,
Plot no.C/1, 'G' Block,
Bandra Kurla Complex,
Bandra (East), Mumbai 400 051

Stock Symbol: JBCHEPHARM

Dear Sir,


Sub : Unaudited Financial Results for the quarter/half year ended on September 30, 2011.

Enclosed please find unaudited financial results for the quarter/half year ended on September 30, 2011. These financial results have been approved and taken on record by the board of directors at its meeting held today.

We request you to take the above on record.

Thanking you,

Yours faithfully,
for J. B. Chemicals & Pharmaceuticals Limited


M. C. Mehta
Company Secretary - General Manager



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAM : DOCTORS AID, MUMBAI.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

http://www.uniquepharma.com

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2011

Rs. in Lakhs

Sr. No.	PARTICULARS	QUARTER ENDED		HALF YEAR ENDED		YEAR ENDED
		30/09/2011 (Unaudited)	30/09/2010 (Unaudited)	30/09/2011 (Unaudited)	30/09/2010 (Unaudited)	31/03/2011 (Audited)
1	a) Net Sales (Net of excise)	16,077.14	23,314.14	33,821.55	39,201.11	78,757.94
	b) Other Operating Income	3,287.93	433.09	3,800.03	867.48	1,912.61
	Total Income	19,365.07	23,747.23	37,621.58	40,068.59	80,670.55
2	Expenditure					
	a) (Increase)/Decrease in Stock in Trade & WIP	500.01	211.11	742.28	577.70	(1,286.13)
	b) Consumption of Raw Materials	5,718.18	5,601.02	10,828.09	9,781.36	20,900.33
	c) Purchase of Traded Goods	1,322.75	1,332.32	2,711.42	2,674.79	4,691.52
	d) Employees Cost	2,130.96	2,919.09	5,241.26	5,401.14	11,642.70
	e) Depreciation	567.50	547.50	1,135.00	1,095.00	2,265.08
	f) Sales Promotion & Publicity	1,015.00	3,066.07	2,269.04	4,197.63	10,527.89
	g) Exchange Fluctuation Suffered (Gain)/Loss	(134.49)	259.69	(139.81)	254.76	16.75
	h) Other Expenditure	4,301.91	4,742.60	8,170.69	8,104.78	17,234.34
	Total	15,421.82	18,679.40	30,957.97	32,087.16	65,992.48
3	Profit from operations before Other Income & Interest (1-2)	3,943.25	5,067.83	6,663.61	7,981.43	14,678.07
4	Other Income	1,361.63	143.76	1,779.96	237.16	586.79
5	Profit before Interest (3+4)	5,304.88	5,211.59	8,443.57	8,218.59	15,264.86
6	Interest	186.34	204.49	367.00	388.17	737.30
7	Profit after Interest but before Exchange Fluctuation Gain / (Loss) (5-6)	5,118.54	5,007.10	8,076.57	7,830.42	14,527.56
8	Exchange Fluctuation Gain / (Loss)	(1,912.93)	245.80	(2,182.73)	(109.63)	(422.22)
9	Profit after Interest but before Exceptional Items (7-8)	3,205.61	5,252.90	5,893.84	7,720.79	14,105.34
10	Exceptional Income (Net)	76,059.34	-	76,059.34	-	-
11	Profit from Ordinary Activities Before Tax (9+10)	79,264.95	5,252.90	81,953.18	7,720.79	14,105.34
12	Tax Expenses :					
	Current Tax	17,203.00	1,049.00	17,956.00	1,544.00	2,810.00
	MAT Credit Entitlement	-	(260.00)	-	(340.00)	(550.00)
	Deferred Tax	66.61	2.74	96.92	(11.46)	19.63
	Short/(Excess) Provision for Taxation for prior year	-	-	-	(2.34)	6.25
13	Profit from Ordinary Activities After Tax (11-12)	61,995.34	4,461.16	63,900.26	6,530.59	11,819.46
14	Paid-up Equity Share Capital (Face Value Rs. 2/- per share)	1,694.10	1,688.76	1,694.10	1,688.76	1,690.34
15	Reserves (excluding Revaluation Reserve) as per balance sheet of previous accounting year	-	-	-	-	69,637.93
16	Earnings Per Share (EPS)					
	a) Basic (Not annualised)	73.30	5.29	75.56	7.74	14.00
	b) Diluted (Not annualised)	73.15	5.28	75.39	7.73	13.96
17	Public Shareholding					
	No. of shares	37,850,710	37,580,135	37,850,710	37,580,135	37,663,735
	% of shareholding	44.69	44.51	44.69	44.51	44.56
18	Promoters and Promoter Group Shareholding					
	a) Pledged/Encumbered					
	Number of shares	-	-	-	-	-
	Percentage of shares (as a % of the shareholding of promoter and promoter group)	-	-	-	-	-
	Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-
	b) Non-encumbered					
	Number of shares	46,854,090	46,858,090	46,854,090	46,858,090	46,853,090
	Percentage of shares (as a % of the shareholding of promoter and promoter group)	100	100	100	100	100
	Percentage of shares (as a % of the total share capital of the company)	55.31	55.49	55.31	55.49	55.44

Unique



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAM : DOCTORS AID, MUMBAI.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

http ://www.uniquepharma.com

NOTES :

1. The above financial results have been reviewed by the audit committee and approved by the board of directors at their meeting held on October 19, 2011.
2. The statutory auditors have carried out a limited review of the above unaudited financial results for the quarter and half year ended on September 30, 2011.
3. The quarter witnessed volatility in Rupee - US\$ rate movement. Consequently, the profit for the quarter before exceptional item was significantly affected by exchange fluctuation loss (translation) provision of Rs.19.13 crores made consequent to weakening of Rupee during the quarter.
4. The exceptional item represent profit of Rs.754.53 crores on sale of Russia-CIS OTC products business and Rs.6.07 crores on transfer of worldwide rights to three trademarks viz. Doktor Mom, Rinza and Fitovit, to Cilag GmbH International, Switzerland (Cilag), a wholly owned subsidiary of Johnson & Johnson, US. This business stood transferred to Cilag w.e.f. 14.07.2011. Hence, the financial results for the quarter are strictly not comparable.
5. The other operating income includes dividend of Rs. 24.97 crores received from the company's Russian subsidiary. This income may not recur.
6. The other income mainly represents the income on investments.
7. During the quarter, Unique Pharmaceutical Laboratories S.R.L., Romania, a wholly owned subsidiary, was voluntarily dissolved.
8. The special interim dividend declared by the board of directors on August 19, 2011 has been paid/dispatched on September 9, 2011.
9. There were no outstanding investor complaints at the beginning of the quarter. The company received 22 complaints from the investors during the quarter, which have been disposed of during the quarter.
10. The company is engaged in a single segment of activity namely, "Pharmaceuticals".
11. During the quarter, the company allotted 78,475 equity shares against exercise of stock options.
12. The statement of assets and liabilities as of September 30, 2011 is as under:

Particulars	Standalone		
	Unaudited		Audited
	30-Sep-11	30-Sep-10	31-Mar-11
Shareholders' Funds			
(a) Capital	1,694.10	1,688.76	1,690.34
(b) Reserves and Surplus	94,306.12	66,253.78	69,637.93
Loan Funds	22,077.50	15,894.92	16,856.32
Deferred Tax Liability	1,540.54	1,412.53	1,443.62
Total	119,618.26	85,249.99	89,628.21
FIXED ASSETS	23,145.62	22,155.21	22,894.44
INVESTMENTS	56,149.80	11,109.36	12,328.84
CURRENT ASSETS, LOANS AND ADVANCES			
(a) Inventories	7,678.23	7,095.04	8,178.22
(b) Sundry Debtors	16,721.90	40,991.28	38,545.42
(c) Cash and Bank balances	27,067.16	10,724.55	12,291.77
(d) Loans and advances	11,909.26	6,611.50	6,488.05
Less: Current Liabilities and Provisions			
(a) Liabilities	11,864.64	11,906.68	7,688.67
(b) Provisions	11,189.07	1,530.27	3,409.86
Total	119,618.26	85,249.99	89,628.21

13. Previous quarter's / period's figures have been regrouped / re-stated, wherever necessary.

For J.B. CHEMICALS & PHARMACEUTICALS LTD.

J.B. MODY
CHAIRMAN & MANAGING DIRECTOR

Place : Mumbai
Date : October 19, 2011